This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing the cretostimogene grenadenorepvec data as it continues to demonstrate best-in-class durability of response as well as consistent and compelling safety and efficacy

Ticker(s): CGON, TARA, AURA, PFE

Who's the expert?

Institution: Premier Medical Association 

  • Urologist with 30+ years of experience and has contributed to several articles regarding the latest developments in urology conditions and treatments and is the recipient of the American Urological Association Grand Prize for clinical research for work performed regarding bladder cancer.
  • Manages 250 NMIBC patients 
  • Familiar with the latest results from BOND-003 Phase 3 Trial

Interview Goal
To better understand the cretostimogene grenadenorepvec data and the overall NMIBC landscape. 

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.